New hope for liver patients: steroid combo trial targets Tough-to-Treat PBC
NCT ID NCT06591468
First seen Jan 06, 2026 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This study looks at whether adding prednisone (a steroid) to the standard medicine UDCA can help people with primary biliary cholangitis (PBC) who also have moderate-to-severe interface hepatitis. About 244 adults aged 18-75 with this condition will take part. The goal is to see if the combination improves liver test results and reduces symptoms like itching and fatigue, while monitoring safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China
-
Xijing hospital
Xi'an, Shaanxi, 710032, China
Conditions
Explore the condition pages connected to this study.